CINCINNATI--(BUSINESS WIRE)--Aug. 9, 2006--Meridian Bioscience, Inc., (NASDAQ:VIVO - News) today provided the financial community with guidance regarding the Company’s fiscal 2007 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2007, management expects net sales to be in the range of $118 to $123 million and per share diluted earnings to be between $0.83 and $0.87. The per share estimates assume an increase in average shares outstanding from approximately 26.8 million at fiscal 2006 year end to 27 million at fiscal 2007 year end. Net income is expected to increase between 20% and 25% from fiscal 2006 to fiscal 2007. The sales and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2007.
